DMH1: Selective BMP Type I Receptor Inhibitor for Precise ALK2 Modulation

Executive Summary: DMH1 (B3686, APExBIO) is a highly selective inhibitor of bone morphogenetic protein (BMP) type I receptors, specifically targeting ALK2 with an IC₅₀ of 107.9 nM in vitro, while exhibiting negligible activity against VEGF signaling and other kinases such as KDR, ALK5, AMPK, and PDGFRβ (APExBIO). In cellular assays, DMH1 potently inhibits ALK2 and ALK3-mediated BMP signaling (IC₅₀ < 0.5 μM) and does not interfere with p38/MAP kinase or Activin A-induced Smad2 activation (Yang 2025). DMH1 demonstrates significant in vivo antitumor activity in non-small cell lung cancer (NSCLC) models by suppressing phosphorylation of Smad1/5/8 and downregulating Id1–3 gene expression. The compound is insoluble in water and ethanol but dissolves in DMSO at ≥9.51 mg/mL, requiring storage at -20°C. These properties make DMH1 a robust tool for research in BMP signaling modulation and translational oncology (APExBIO).

Biological Rationale

The bone morphogenetic protein (BMP) pathway orchestrates diverse cellular processes, including proliferation, differentiation, and migration in development and disease (Yang 2025). Dysregulation of BMP signaling is implicated in tumorigenesis, fibrosis, and impaired tissue regeneration. BMP type I receptors, especially ALK2 (also known as ACVR1), are critical mediators transmitting BMP ligand signals to intracellular effectors, notably the Smad1/5/8 proteins. Selective inhibition of ALK2 is essential for dissecting BMP-specific effects without disrupting parallel pathways such as TGF-β, VEGF, or MAPK. This specificity enables researchers to modulate self-renewal and differentiation balance in organoids, and to interrogate the role of BMP signaling in cancer cell behavior and tissue morphogenesis (see detailed mechanistic review; this article clarifies newly benchmarked selectivity data not covered in prior reviews).

Mechanism of Action of DMH1

DMH1 is a small-molecule analog of dorsomorphin designed for enhanced selectivity against BMP type I receptors. It competitively inhibits the ATP-binding site of ALK2, and to a lesser degree ALK3, effectively blocking BMP-induced phosphorylation of Smad1/5/8. At concentrations <0.5 μM in cell-based assays, DMH1 suppresses downstream gene expression (Id1, Id2, Id3) without affecting Activin A-induced Smad2 activation or p38/MAPK signaling (Yang 2025). DMH1 does not inhibit VEGF receptor 2 (KDR), ALK5, AMPK, or PDGFRβ at pharmacologically relevant concentrations. This selectivity is critical for studies demanding BMP pathway isolation, such as in human intestinal organoids where precise modulation of self-renewal and differentiation is essential (see selectivity profile discussion; this article updates in vivo potency benchmarks).

Evidence & Benchmarks

• DMH1 inhibits ALK2 with an IC₅₀ of 107.9 nM in biochemical assays (APExBIO product data; DMH1).
• In cell-based systems, DMH1 blocks ALK2 and ALK3 signaling with IC₅₀ <0.5 μM, without suppressing Smad2/3 or MAPK pathways (Yang 2025).
• DMH1 does not inhibit VEGF receptor 2 (KDR), ALK5, AMPK, or PDGFRβ up to 10 μM (APExBIO, DMH1).
• In A549 NSCLC xenograft mouse models, DMH1 at 10 mg/kg significantly reduces tumor volume by approximately 50% and extends tumor doubling time (Yang 2025, Table 2, DOI).
• DMH1 downregulates Id1, Id2, and Id3 gene expression and inhibits cancer cell migration, invasion, and proliferation in vitro (Yang 2025, Figure 3, DOI).
• In human intestinal organoid cultures, DMH1 enables controlled modulation of self-renewal and differentiation balance, contributing to increased cellular diversity and scalability (Yang 2025).

Applications, Limits & Misconceptions

DMH1 is validated in multiple research domains, primarily:

• Non-Small Cell Lung Cancer (NSCLC) Research: Enables targeted inhibition of BMP signaling to study tumor growth, gene regulation, and cell death.
• Organoid Engineering: Facilitates precise modulation of stem cell fate and differentiation, advancing high-throughput and reproducible organoid culture systems (Unlocking Translational Potential; this article expands on in vivo NSCLC data).
• Developmental Biology: Dissects BMP-mediated processes without confounding VEGF or TGF-β pathway effects.
• Pharmacological Benchmarking: Serves as a reference compound for BMP pathway screening.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: DMH1’s activity is highly selective for ALK2/ALK3; it does not substantially inhibit KDR, ALK5, AMPK, or PDGFRβ.
• Limited solubility in aqueous buffers: DMH1 is insoluble in water and ethanol; DMSO is required for stock solutions.
• Short-term stability: Solutions are recommended for immediate use; prolonged storage in solution, even at -20°C, can reduce potency (APExBIO).
• Not effective in Activin/TGF-β pathway inhibition: DMH1 does not block Smad2 phosphorylation or Activin-induced processes.
• Not a clinical drug: DMH1 is for research use only and not approved for human or veterinary therapeutic applications.

Workflow Integration & Parameters

For optimal use, DMH1 (APExBIO B3686) should be dissolved in DMSO at ≥9.51 mg/mL. Warming to 37°C and ultrasonic shaking may enhance solubility. Working concentrations in cell culture typically range from 0.1–5 μM, depending on assay sensitivity and target cell type. For in vivo mouse studies, dosing regimens such as 10 mg/kg have demonstrated significant tumor growth inhibition. DMH1 should be stored as a powder or concentrated DMSO solution at -20°C, avoiding repeated freeze-thaw cycles. Application in organoid systems enables reversible modulation of self-renewal and differentiation, supporting scalable, high-diversity cultures (see dynamic cell fate control in organoids; this article provides more granular workflow parameters for BMP-specific modulation).

Conclusion & Outlook

DMH1 stands as a gold-standard, highly selective BMP type I receptor inhibitor for research applications in oncology, developmental biology, and organoid engineering. Its robust selectivity and reproducible efficacy underpin a wide range of experimental workflows. Future studies will likely exploit DMH1’s precision to dissect BMP-driven disease mechanisms and to engineer tissue models with nuanced cell fate outcomes. For detailed specifications and ordering, consult the official product page for DMH1 (APExBIO B3686).